Cargando…

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgently awaited. A rising body of evidence supports the notion that microRNAs (miRNAs), master regulators of eukaryotic gene expression, may exert anti-MM activity. Here, we evaluated the activity of synth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Martino, Maria Teresa, Campani, Virginia, Misso, Gabriella, Gallo Cantafio, Maria Eugenia, Gullà, Annamaria, Foresta, Umberto, Guzzi, Pietro Hiram, Castellano, Maria, Grimaldi, Anna, Gigantino, Vincenzo, Franco, Renato, Lusa, Sara, Cannataro, Mario, Tagliaferri, Pierosandro, De Rosa, Giuseppe, Tassone, Pierfrancesco, Caraglia, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937395/ https://www.ncbi.nlm.nih.gov/pubmed/24587182 http://dx.doi.org/10.1371/journal.pone.0090005

Ejemplares similares

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
por: Scognamiglio, Immacolata, et al.
Publicado: (2014)

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2013)

Mir-34: A New Weapon Against Cancer?
por: Misso, Gabriella, et al.
Publicado: (2014)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

Analysis of miRNA, mRNA, and TF interactions through network-based methods
por: Guzzi, Pietro H, et al.
Publicado: (2015)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
por: Zarone, Mayra Rachele, et al.
Publicado: (2017)

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2015)

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
por: Amodio, Nicola, et al.
Publicado: (2012)

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity
por: Raimondi, Lavinia, et al.
Publicado: (2014)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach
por: Coutinho, Maria Francisca, et al.
Publicado: (2020)

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
por: Grillone, Katia, et al.
Publicado: (2020)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
por: Morelli, E, et al.
Publicado: (2015)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
por: Di Martino, Maria T, et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
por: Amodio, Nicola, et al.
Publicado: (2019)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma
por: Juli, Giada, et al.
Publicado: (2019)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma
por: Misso, Gabriella, et al.
Publicado: (2019)

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jp2qlj8jh3sdib4f2615idpc5